These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24621104)

  • 1. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant.
    Horwedel TA; Bowman LJ; Saab G; Brennan DC
    Transpl Infect Dis; 2014 Apr; 16(2):261-9. PubMed ID: 24621104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infections during induction therapy for children with acute lymphoblastic leukemia. the role of sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis.
    Rungoe C; Malchau EL; Larsen LN; Schroeder H
    Pediatr Blood Cancer; 2010 Aug; 55(2):304-8. PubMed ID: 20583218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
    Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.
    Schrøder H; Agger KE; Rosthøj S; Carlsen NT; Schmiegelow K
    Dan Med Bull; 2001 Nov; 48(4):275-7. PubMed ID: 11767129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole.
    Baden LR; Katz JT; Franck L; Tsang S; Hall M; Rubin RH; Jarcho J
    Transplantation; 2003 Feb; 75(3):339-43. PubMed ID: 12589155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia.
    EBPG Expert Group on Renal Transplantation
    Nephrol Dial Transplant; 2002; 17 Suppl 4():36-9. PubMed ID: 12091642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis.
    Fu W; Barahona M; Harkness T; Cohen E; Reardon D; Yoo PS
    Clin Transplant; 2020 Nov; 34(11):e14067. PubMed ID: 32810885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
    Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
    Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients.
    Mitsides N; Greenan K; Green D; Middleton R; Lamerton E; Allen J; Redshaw J; Chadwick PR; Subudhi CP; Wood G
    Nephrology (Carlton); 2014 Mar; 19(3):157-63. PubMed ID: 24387294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.
    Chung JB; Armstrong K; Schwartz JS; Albert D
    Arthritis Rheum; 2000 Aug; 43(8):1841-8. PubMed ID: 10943875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nocardia farcinica pericarditis after kidney transplantation despite prophylaxis.
    McPhee L; Stogsdill P; Vella JP
    Transpl Infect Dis; 2009 Oct; 11(5):448-53. PubMed ID: 19508699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].
    Agger KE; Schrøder H; Rosthøj S; Carlsen NT; Schmiegelow K
    Ugeskr Laeger; 2002 Jan; 164(4):488-92. PubMed ID: 11838420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
    Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
    Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.